Coffee in Moderation... Safe and Beneficial for Patients with Atrial Fibrillation
In a result that challenges and corrects traditional medical advice that doctors have provided for decades regarding the necessity of avoiding caffeine, a recent randomized clinical trial revealed that consuming at least one cup of caffeinated coffee daily did not worsen the condition of patients with atrial fibrillation; rather, it was associated with a lower rate of arrhythmia recurrence.
The study, conducted by researchers Christopher Wong and Gregory Marcus, was published in the journal Cardiovascular Research and relied on data from the Decaf randomized trial, the primary results of which were published in the medical journal JAMA.
The trial, which is the first of its kind to directly test the effect of caffeinated coffee on patients with atrial fibrillation, included 200 patients suffering from persistent atrial fibrillation or atrial flutter with a history of atrial fibrillation, all of whom were candidates for electrical cardioversion. The study required participants to have consumed at least one cup of coffee daily over the previous five years, including those who had stopped based on medical advice or personal conviction.
Following successful rhythm control procedures, participants were randomly divided equally into two groups: the first group committed to drinking at least one cup of caffeinated coffee daily, while the second group abstained from all coffee, including decaffeinated varieties, and any other caffeinated products for six months. The average coffee consumption in the drinking group was seven cups per week, compared to zero in the abstention group.
The results showed that participants who consumed coffee experienced a 39 percent reduction in the risk of clinically diagnosed atrial fibrillation or atrial flutter recurrence compared to those who abstained from caffeine, with a hazard ratio of 0.61. No differences in side effects were recorded between the two groups. Researchers attribute this outcome to potential biological mechanisms, including caffeine’s blockade of adenosine receptors, which may facilitate arrhythmias, as well as the anti-inflammatory, antioxidant, and anti-fibrotic properties potentially possessed by coffee components.
Nevertheless, the research team emphasized that the sample size was relatively limited, as approximately 2,000 patients needed to be screened to identify 200 eligible participants, calling for additional randomized trials before changing current clinical guidelines. The researchers concluded that moderate consumption of caffeinated coffee, at a rate of approximately one cup per day, is unlikely to worsen atrial fibrillation in most patients, while it remains to be determined whether coffee itself offers a true protective benefit.
